Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 13, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| July 12, 2018 | Ordinary Shares (25p) | £15.7218 | 1,452 shares | London Stock Exchange |
Note: Total volume is the aggregate of three separate transactions reported in the filing.
Material Changes
The filing reports no material changes to the company's financial position or operations. It details routine acquisitions of ordinary shares by three individuals following the re-investment of dividends paid on July 12, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed as part of a dividend re-investment plan.
Key Facts for Investor Verification
- Transaction Nature: All reported trades were acquisitions of ordinary shares via dividend re-investment, not open market purchases or sales.
- Participants: Transactions involved Mrs. V A Whyte (Company Secretary), Mr. I W Whyte (PCA of Mrs. Whyte), and Mrs. D Connor (PCA of Mr. R G Connor).
- Share Price: The execution price for all transactions was £15.7218 per share.
- Volume Breakdown: Mrs. V A Whyte acquired 105 shares; Mr. I W Whyte acquired 496 shares; Mrs. D Connor acquired 851 shares.